Past Issues

Immunotherapy and Cardiovascular Health - A Cause for Concern?

2023

In this Perspectives on the Science piece we reflect on the impact of ‘Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque’ by Drobni et al.
May 1, 2023
David M. Miller, Laura K. Ferris, Sameer Gupta, Isaac Brownell, Sophia Z. Shalhout

Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?

2023
Melanoma
Neoadjuvant
Adjvuant

In this Perspectives on the Science piece we reflect on the impact of the recently published SWOG S1801 trial.
Apr 15, 2023
Serena Vilasi, David M. Miller, Howard L. Kaufman, Kevin S. Emerick, Sophia Z. Shalhout, Emily Y Kim, Vishal A. Patel, Khalid Garmen, Sameer Gupta, Isaac Brownell

Skin Cancer Chemoprevention for Solid Organ Transplant Recipients - The Search Continues

2023
CSCC

In this Perspectives on the Science piece, we reflect on the impact of the recently published ONTRANS trial.
Mar 22, 2023
Howard L. Kaufman, Vishal A. Patel, Sophia Z. Shalhout, Sameer Gupta, Sonia Cohen, Isaac Brownell, David M. Miller

Lacking Overall IMspiration for Triplet Therapy in Melanoma? A Review of the Interim Analysis of IMspire150.

2023
Melanoma

In this Perspectives on the Science piece, we reflect on the impact of the recently published article by Ascierto et al. in Lancet Oncology that provides interim results from IMspire150.
Feb 4, 2023
David M. Miller, Kevin S. Emerick, Vishal A. Patel, Sonia Cohen, Isaac Brownell, Donald P. Lawrence

Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma: Ready for Prime Time?

2023
Melanoma

In this Perspectives on the Science piece, we reflect on the impact of the recently published article “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma”.
Jan 9, 2023
Emily Y Kim, Sophia Z. Shalhout, Howard L. Kaufman, Kevin S. Emerick, Vishal A. Patel, Khalid Garmen, Isaac Brownell, David M. Miller

Neoadjuvant Nivo/Rela for Resectable Melanoma

2022
Melanoma
Neoadjuvant
Nivo/Rela

In this Perspectives on the Science piece we reflect on the impact of the recently published article “Neoadjuvant relatlimab and nivolumab in resectable melanoma”.
Dec 5, 2022
David M. Miller, Howard L. Kaufman, Kevin S. Emerick, Justine V. Cohen, Emily Y Kim, Sophia Z. Shalhout

Ipi/Nivo for Advanced MCC

2022
Merkel Cell Carcinoma
Ipi/Nivo

In this Perspectives on the Science piece we reflect on the impact of the recently published article “Combined Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy for Advanced Merkel cell carcinoma - A Randomised, Open Label, Phase 2 Trial”.
Nov 21, 2022
Sophia Z. Shalhout, Justine V. Cohen, Khalid Garmen, Emily Y Kim, Sonia Cohen, David M. Miller

Neoadjuvant ICI for Resectable CSCC

2022
CSCC
Neoadjuvant

In this Perspectives on the Science piece we reflect on the impact of the recently published article “Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma”.
Nov 8, 2022
David M. Miller, Vishal A. Patel, Justine V. Cohen, Khalid Garmen, Sophia Z. Shalhout
No matching items

Cover Art
The cover art for Volume 1 Issue 1 was created by David M. Miller using Open AI’s DALL·E software. The image represents a tumor-infiltrating lymphocyte primed to execute effector functions against a neoplastic cell.